Systematic review of the incidence and prevalence of genital warts

H Patel, M Wagner, P Singhal, S Kothari - BMC infectious diseases, 2013 - Springer
Abstract Background Anogenital warts (AGWs) are a common, highly infectious disease
caused by the human papillomavirus (HPV), whose high recurrence rates contribute to direct …

Genital warts

M Steben, SM Garland - Best practice & research Clinical obstetrics & …, 2014 - Elsevier
Anogenital warts (AGWs) are a very common disease. They are caused mostly by low-risk
human papillomaviruses (HPV) 6 and 11, particularly the former. Clinical presentation is …

2019 IUSTI‐Europe guideline for the management of anogenital warts

R Gilson, D Nugent, RN Werner… - Journal of the …, 2020 - Wiley Online Library
This guideline is an update of the 2011 European Guideline for the Management of
Anogenital Warts. It is intended to support best practice in the care of patients with …

Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model–based analysis

N Van de Velde, MC Boily, M Drolet… - Journal of the …, 2012 - academic.oup.com
Background Bivalent and quadrivalent human papillomavirus (HPV) vaccines are now
licensed in several countries. Furthermore, clinical trials examining the efficacy of a …

Impact of human papillomavirus-related genital diseases on quality of life and psychosocial wellbeing: results of an observational, health-related quality of life study in …

G Dominiak-Felden, C Cohet, S Atrux-Tallau, H Gilet… - BMC public health, 2013 - Springer
Background Data on the psychosocial burden of human papillomavirus (HPV)-related
diseases other than cervical cancer are scarce. The objectives of this study were to measure …

Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States

M Brisson, JF Laprise, HW Chesson… - Journal of the …, 2016 - academic.oup.com
Background: Randomized clinical trials have shown the 9-valent human papillomavirus
(HPV) vaccine to be highly effective against types 31/33/45/52/58 compared with the 4 …

Understanding human papillomavirus vaccination intentions: comparative utility of the theory of reasoned action and the theory of planned behavior in vaccine target …

WA Fisher, T Kohut, CMA Salisbury… - The journal of sexual …, 2013 - academic.oup.com
Introduction Human papillomavirus (HPV) is an exceedingly prevalent sexually transmitted
infection with serious medical, sexual, and relationship consequences. HPV vaccine …

Potential cost‐effectiveness of the nonavalent human papillomavirus (HPV) vaccine

M Drolet, JF Laprise, MC Boily… - … Journal of Cancer, 2014 - Wiley Online Library
Randomized clinical trials are currently examining the efficacy of a nonavalent human
papillomavirus (HPV) vaccine, including HPV‐types 6/11/16/18/31/33/45/52/58. Evidence on …

[HTML][HTML] Comparing the cost-effectiveness of two-and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study

JF Laprise, M Drolet, MC Boily, M Jit, C Sauvageau… - Vaccine, 2014 - Elsevier
Background Recent evidence suggests that two doses of HPV vaccines may be as
protective as three doses in the short-term. We estimated the incremental cost-effectiveness …

[HTML][HTML] Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation.

E Thurgar, S Barton, C Karner… - Health Technology …, 2016 - ncbi.nlm.nih.gov
BACKGROUND Typically occurring on the external genitalia, anogenital warts (AGWs) are
benign epithelial skin lesions caused by human papillomavirus infection. AGWs are usually …